For Moderate to Severe Psoriasis, Surveyed U.S. Dermatologists Would Accept a Substantial Decrease in Efficacy ...
21 May 2012, 9:00 am
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, surveyed U.S.

NHS to look again at Megrahi prostate drug
13 May 2012, 6:47 pm
The company behind a prostate cancer drug credited with keeping Abdelbaset al-Megrahi alive, has asked again for the treatment to be made available to NHS patients in Scotland.

Prostate cancer drug resubmitted
12 May 2012, 7:05 pm
The company behind a drug which could extend the lives of men suffering from prostate cancer has asked again for the treatment to be made available to NHS patients.

New bid to get cancer drug for Scots patients
12 May 2012, 6:18 pm
THE company behind a drug which could extend the lives of men suffering from prostate cancer has asked again for the treatment to be made available to NHS patients.

Pozen migraine drug licensed to Desitin for commercialization in Europe
8 May 2012, 10:22 am
The migraine headache treatment developed by Pozen (NASDAQ:POZN) now has a partner for commercialization in Europe. Pozen licensed the compound MT 400 to German central nervous system therapies company Desitin in a deal that will pay the Chapel Hill, North Carolina drug developer $3 million up front, plus milestones and royalties from drug sales in the [...]

POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH for MT 400 Migraine Treatment in 29 European Countries
8 May 2012, 6:30 am
POZEN Inc. , a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Desitin Arzneimittel GmbH, for the development and commercialization of MT 400 for the 27 countries of the European Union, as well as Switzerland and Norway.

Recordati: Good First Quarter 2012 Results (Revenue +11.0%, Net Income +7.5%)
8 May 2012, 5:12 am
MILAN, ITALY-- --- Consolidated revenue EUR 219.6 million, + 11.0%.-- Operating income EUR 47.6 million, + 7.5%.-- Net income EUR 33.8 million, + 7.5%.-- Net financial position*: net debt of EUR 54.1 million.-- ...

Dermatological Drugs: World Market Prospects 2012-2022
2 May 2012, 7:36 am
NEW YORK, May 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Dermatological Drugs: World Market Prospects 2012-2022 http://www.reportlinker.com/p0788690/Dermatological-Drugs-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_MedicationReport ...

RECORDATI Acquires Six OTC Products in Germany
24 April 2012, 11:24 am
MILAN, ITALY-- - Recordati announces the acquisition of themarketingauthorizations, the trademarks and additional assets concerning sixOTCpharmaceuticals for Germany from cilag GmbH International and McNeil ...

Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
24 April 2012, 7:05 am
BERKELEY HEIGHTS, N.J. -- Genta Incorporated announced today the appointments of Dr. Brian Leyland-Jones and Richard J. Moran, as members of the Company's Board of Directors. The Company also announced ...